Desvenlafaxine Succinate

CHEMBL1201728 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
399.5 g/mol
LogP
Phase
4

The succinate salt form of desvenlafaxine, an SNRI antidepressant approved for major depressive disorder. The extended-release tablet allows once-daily dosing.

Peso molecular

399,5000 g/mol

TPSA

119,00 Ų

Áreas terapéuticas

Mecanismo de acción

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O=C(O)CCC(=O)O

InChI

InChI=1S/C16H25NO2.C4H6O4/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8)

Molecular Formula

C20H33NO7

HBD / HBA

5 / 8

Enlaces Rotables

7

Átomos Pesados

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The succinate salt form of desvenlafaxine, an SNRI antidepressant approved for major depressive disorder. The extended-release tablet allows once-daily dosing.

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

Yes, Desvenlafaxine Succinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201728. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6918664. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.